The iShares NASDAQ Biotechnology ETF was up more than 3 percent on the week, but down nearly 24 percent this year.
CNBC's Meg Tirrell reports on the bounce in the biotech sector and how some names could be a good buy at the moment.
CNBC's Meg Tirrell tracks the IBB, which is getting a boost from a new report on the health of Medicare.
SYDNEY, June 14- Mesoblast Ltd shares lost more than a third of their value on Tuesday, after drugs giant Teva Pharmaceutical Industries ended a research partnership with the experimental stem cell therapy company. The Australia- based Mesoblast said on Tuesday it had regained full rights to its experimental therapy for advanced chronic heart failure, which...
June 13- Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries. While Teva returned its rights to the potential blockbuster treatment without any financial payment, the Israel- based generic drugmaker can...
The Hollywood actress will play the role of Theranos CEO Elizabeth Holmes on the big screen.
Perkins helped grow Silicon Valley's venture capital industry, playing a major role in the early years of the computer and biotech sectors.
The "Fast Money" traders weighed election risks for biotech after Obama officially endorsed Hillary Clinton.
Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.
CNBC's Meg Tirrell looks at some pharma and biotech stocks that are making news today.
Shares of Juno Therapeutics jumped on optimistic data from clinical trials of its acute lymphoblastic leukemia therapy.
The "FMHR" traders discuss the biotech and pharmaceuticals trade and give their best bets for stocks.
CNBC's Meg Tirrell reports on what bio-pharma breakthroughs to expect out of this year's ASCO conference, and the "FMHR" traders weigh in on the biotech sector.
Dennis Davitt, Harvest Volatility Advisors, and Rich Ross, Evercore ISI, discuss the biotech sector with Melissa Lee.
Saker Nusseibeh, CEO of Hermes Investment Management, recommends the theme of intellectual property, such as IT and pharma stocks, to investors.
The "FMHR" traders discuss the rebound in the biotech sector and give some picks.
Dennis Gartman, founder, editor & publisher of The Gartman Letter, comments on Monsanto's decision to reject the Bayer acquisition proposal.
A start-up is giving its employees a new Tesla car, which is expected to cost $35-thousand each.
Kurt Graves, Intarcia Therapeutics CEO, discusses how the company's product eliminates the need for daily injections for type 2 diabetes and instead delivers a steady dose of medicine over the course of a year,
CNBC's Mary Thompson looks ahead at the day's market action including energy stocks and surging oil prices.